First Header Logo Second Header Logo

Waldemar Debinski MD, PhD

TitleProfessor
InstitutionWake Forest School of Medicine
DepartmentCancer Biology
Address
vCardDownload vCard
    Other Positions
    TitleProfessor
    InstitutionWake Forest School of Medicine
    DepartmentMicrobiology and Immunology

    TitleProfessor
    InstitutionWake Forest School of Medicine
    DepartmentNeurological Surgery

    TitleProfessor
    InstitutionWake Forest School of Medicine
    DepartmentRadiation Oncology

    TitleDirector
    InstitutionWake Forest School of Medicine
    DepartmentFormer Center - Brain Tumor Center of Excellence


    Collapse Research 
    Collapse research activities and funding
    R01CA074145     (DEBINSKI, WALDEMAR)Jul 1, 1998 - Jun 30, 2021
    NIH
    High-Grade Astrocytoma-Specific Molecular Targeting
    Role: Principal Investigator
    R01CA118261     (DEBINSKI, WALDEMAR)Dec 28, 2005 - Nov 30, 2011
    NIH
    Molecular Requirements for Recombinant Cytotoxins Efficacy
    Role: Principal Investigator
    R13CA121777     (DEBINSKI, WALDEMAR)Sep 1, 2006 - Nov 30, 2012
    NIH
    Ephrins and Cancer
    Role: Principal Investigator
    R01CA139099     (DEBINSKI, WALDEMAR)Jan 1, 2010 - Nov 30, 2015
    NIH
    Molecular Combinatorial Therapy of Glioblastoma Multiforme
    Role: Principal Investigator
    P01CA207206     (DEBINSKI, WALDEMAR)Aug 17, 2017 - Jul 31, 2022
    NIH
    Maximizing Local Access to Therapeutic Deliveries in Glioblastoma
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Mao C, Li F, Zhao Y, Debinski W, Ming X. P-glycoprotein-targeted photodynamic therapy boosts cancer nanomedicine by priming tumor microenvironment. Theranostics. 2018; 8(22):6274-6290. PMID: 30613297.
      Citations:    
    2. Sharma P, Debinski W. Receptor-Targeted Glial Brain Tumor Therapies. Int J Mol Sci. 2018 Oct 25; 19(11). PMID: 30366424.
      Citations:    
    3. Soike MH, McTyre ER, Shah N, Puchalski RB, Holmes JA, Paulsson AK, Miller LD, Cramer CK, Lesser GJ, Strowd RE, Hinson WH, Mott RT, Johnson AJ, Lo HW, Laxton AW, Tatter SB, Debinski W, Chan MD. Glioblastoma radiomics: can genomic and molecular characteristics correlate with imaging response patterns? Neuroradiology. 2018 Oct; 60(10):1043-1051. PMID: 30094640.
      Citations:    
    4. Renfrow JJ, Soike MH, Debinski W, Ramkissoon SH, Mott RT, Frenkel MB, Sarkaria JN, Lesser GJ, Strowd RE. Hypoxia-inducible factor 2a: a novel target in gliomas. Future Med Chem. 2018 09 01; 10(18):2227-2236. PMID: 30089425.
      Citations:    
    5. Mao C, Zhao Y, Li F, Li Z, Tian S, Debinski W, Ming X. P-glycoprotein targeted and near-infrared light-guided depletion of chemoresistant tumors. J Control Release. 2018 09 28; 286:289-300. PMID: 30081143.
      Citations:    
    6. McTyre E, Lucas JT, Helis C, Farris M, Soike M, Mott R, Laxton AW, Tatter SB, Lesser GJ, Strowd RE, Lo HW, Debinski W, Chan MD. Outcomes for Anaplastic Glioma Treated With Radiation Therapy With or Without Concurrent Temozolomide. Am J Clin Oncol. 2018 08; 41(8):813-819. PMID: 28301347.
      Citations:    
    7. Xing F, Liu Y, Wu SY, Wu K, Sharma S, Mo YY, Feng J, Sanders S, Jin G, Singh R, Vidi PA, Tyagi A, Chan MD, Ruiz J, Debinski W, Pasche BC, Lo HW, Metheny-Barlow LJ, D'Agostino RB, Watabe K. Loss of XIST in Breast Cancer Activates MSN-c-Met and Reprograms Microglia via Exosomal miRNA to Promote Brain Metastasis. Cancer Res. 2018 08 01; 78(15):4316-4330. PMID: 30026327.
      Citations:    
    8. Su W, Hong L, Xu X, Huang S, Herpai D, Li L, Xu Y, Truong L, Hu WY, Wu X, Xiao C, Zhang W, Han J, Debinski W, Xiang R, Sun P. miR-30 disrupts senescence and promotes cancer by targeting both p16INK4A and DNA damage pathways. Oncogene. 2018 10; 37(42):5618-5632. PMID: 29907771.
      Citations:    
    9. Rimkus TK, Carpenter RL, Sirkisoon S, Zhu D, Pasche BC, Chan MD, Lesser GJ, Tatter SB, Watabe K, Debinski W, Lo HW. Truncated Glioma-Associated Oncogene Homolog 1 (tGLI1) Mediates Mesenchymal Glioblastoma via Transcriptional Activation of CD44. Cancer Res. 2018 05 15; 78(10):2589-2600. PMID: 29463580.
      Citations:    
    10. Jimenez H, Blackman C, Lesser G, Debinski W, Chan M, Sharma S, Watabe K, Lo HW, Thomas A, Godwin D, Blackstock W, Mudry A, Posey J, O'Connor R, Brezovich I, Bonin K, Kim-Shapiro D, Barbault A, Pasche B. Use of non-ionizing electromagnetic fields for the treatment of cancer. Front Biosci (Landmark Ed). 2018 Jan 01; 23:284-297. PMID: 28930547.
      Citations:    
    11. Debinski W. When better still might not be good enough. Transl Cancer Res. 2017 Oct; 6(Suppl 7):S1244-S1247. PMID: 30214854.
      Citations:    
    12. Ivey JW, Latouche EL, Richards ML, Lesser GJ, Debinski W, Davalos RV, Verbridge SS. Enhancing Irreversible Electroporation by Manipulating Cellular Biophysics with a Molecular Adjuvant. Biophys J. 2017 Jul 25; 113(2):472-480. PMID: 28746857.
      Citations:    
    13. Sattiraju A, Solingapuram Sai KK, Xuan A, Pandya DN, Almaguel FG, Wadas TJ, Herpai DM, Debinski W, Mintz A. IL13RA2 targeted alpha particle therapy against glioblastomas. Oncotarget. 2017 Jun 27; 8(26):42997-43007. PMID: 28562337.
      Citations:    
    14. Sonawane P, Choi YA, Pandya H, Herpai DM, Fokt I, Priebe W, Debinski W. Novel Molecular Multilevel Targeted Antitumor Agents. Cancer Transl Med. 2017 May-Jun; 3(3):69-79. PMID: 28825042.
      Citations:    
    15. Carpenter RL, Sirkisoon S, Zhu D, Rimkus T, Harrison A, Anderson A, Paw I, Qasem S, Xing F, Liu Y, Chan M, Metheny-Barlow L, Pasche BC, Debinski W, Watabe K, Lo HW. Combined inhibition of AKT and HSF1 suppresses breast cancer stem cells and tumor growth. Oncotarget. 2017 Sep 26; 8(43):73947-73963. PMID: 29088759.
      Citations:    
    16. Rossmeisl JH, Hall-Manning K, Robertson JL, King JN, Davalos RV, Debinski W, Elankumaran S. Expression and activity of the urokinase plasminogen activator system in canine primary brain tumors. Onco Targets Ther. 2017; 10:2077-2085. PMID: 28442916.
      Citations:    
    17. Sai KKS, Sattiraju A, Almaguel FG, Xuan A, Rideout S, Krishnaswamy RS, Zhang J, Herpai DM, Debinski W, Mintz A. Peptide-based PET imaging of the tumor restricted IL13RA2 biomarker. Oncotarget. 2017 Aug 01; 8(31):50997-51007. PMID: 28881623.
      Citations:    
    18. Stuart CH, Riley KR, Boyacioglu O, Herpai DM, Debinski W, Qasem S, Marini FC, Colyer CL, Gmeiner WH. Selection of a Novel Aptamer Against Vitronectin Using Capillary Electrophoresis and Next Generation Sequencing. Mol Ther Nucleic Acids. 2016 Nov 15; 5(11):e386. PMID: 27845768.
      Citations:    
    19. Randolph DM, McTyre ER, Paulsson AK, Holmes JA, Hinson WH, Lesser GJ, Strowd R, Lo HW, Laxton AW, Tatter SB, Debinski W, Chan MD. Impact of timing of radiotherapy in patients with newly diagnosed glioblastoma. Clin Neurol Neurosurg. 2016 Dec; 151:73-78. PMID: 27816029.
      Citations:    
    20. Ferluga S, Tomé CM, Herpai DM, D'Agostino R, Debinski W. Simultaneous targeting of Eph receptors in glioblastoma. Oncotarget. 2016 Sep 13; 7(37):59860-59876. PMID: 27494882.
      Citations:    
    21. Qian X, Tan H, Zhang J, Liu K, Yang T, Wang M, Debinskie W, Zhao W, Chan MD, Zhou X. Identification of biomarkers for pseudo and true progression of GBM based on radiogenomics study. Oncotarget. 2016 Aug 23; 7(34):55377-55394. PMID: 27421136.
      Citations:    
    22. Gmeiner WH, Debinski W, Milligan C, Caudell D, Pardee TS. The applications of the novel polymeric fluoropyrimidine F10 in cancer treatment: current evidence. Future Oncol. 2016 Sep; 12(17):2009-20. PMID: 27279153.
      Citations:    
    23. Rossmeisl JH, Clapp K, Pancotto TE, Emch S, Robertson JL, Debinski W. Canine Butterfly Glioblastomas: A Neuroradiological Review. Front Vet Sci. 2016; 3:40. PMID: 27458589.
      Citations:    
    24. Zhang J, Yu H, Qian X, Liu K, Tan H, Yang T, Wang M, Li KC, Chan MD, Debinski W, Paulsson A, Wang G, Zhou X. Pseudo progression identification of glioblastoma with dictionary learning. Comput Biol Med. 2016 06 01; 73:94-101. PMID: 27100835.
      Citations:    
    25. Haughton ME, Chan MD, Watabe K, Bonomi M, Debinski W, Lesser GJ, Ruiz J. Treatment of brain metastases of lung cancer in the era of precision medicine. Front Biosci (Elite Ed). 2016 Jan 01; 8:219-32. PMID: 26709658.
      Citations:    
    26. Hughes RT, Black PJ, Page BR, Lucas JT, Qasem SA, Watabe K, Ruiz J, Laxton AW, Tatter SB, Debinski W, Chan MD. Local control of brain metastases after stereotactic radiosurgery: the impact of whole brain radiotherapy and treatment paradigm. J Radiosurg SBRT. 2016; 4(2):89-96. PMID: 29296433.
      Citations:    
    27. Carpenter RL, Paw I, Zhu H, Sirkisoon S, Xing F, Watabe K, Debinski W, Lo HW. The gain-of-function GLI1 transcription factor TGLI1 enhances expression of VEGF-C and TEM7 to promote glioblastoma angiogenesis. Oncotarget. 2015 Sep 08; 6(26):22653-65. PMID: 26093087.
      Citations:    
    28. Johnson AG, Ruiz J, Hughes R, Page BR, Isom S, Lucas JT, McTyre ER, Houseknecht KW, Ayala-Peacock DN, Bourland DJ, Hinson WH, Laxton AW, Tatter SB, Debinski W, Watabe K, Chan MD. Impact of systemic targeted agents on the clinical outcomes of patients with brain metastases. Oncotarget. 2015 Aug 07; 6(22):18945-55. PMID: 26087184.
      Citations:    
    29. Rodriguez A, Tatter SB, Debinski W. Neurosurgical Techniques for Disruption of the Blood-Brain Barrier for Glioblastoma Treatment. Pharmaceutics. 2015 Aug 03; 7(3):175-87. PMID: 26247958.
      Citations:    
    30. Rossmeisl JH, Andriani RT, Cecere TE, Lahmers K, LeRoith T, Zimmerman KL, Gibo D, Debinski W. Frame-Based Stereotactic Biopsy of Canine Brain Masses: Technique and Clinical Results in 26 Cases. Front Vet Sci. 2015; 2:20. PMID: 26664949.
      Citations:    
    31. Holmes JA, Paulsson AK, Page BR, Miller LD, Liu W, Xu J, Hinson WH, Lesser GJ, Laxton AW, Tatter SB, Debinski W, Chan MD. Genomic predictors of patterns of progression in glioblastoma and possible influences on radiation field design. J Neurooncol. 2015 Sep; 124(3):447-53. PMID: 26186902.
      Citations:    
    32. Paw I, Carpenter RC, Watabe K, Debinski W, Lo HW. Mechanisms regulating glioma invasion. Cancer Lett. 2015 Jun 28; 362(1):1-7. PMID: 25796440.
      Citations:    
    33. Ferluga S, Debinski W. Ephs and Ephrins in malignant gliomas. Growth Factors. 2014 Dec; 32(6):190-201. PMID: 25418012.
      Citations:    
    34. Paulsson AK, Holmes JA, Peiffer AM, Miller LD, Liu W, Xu J, Hinson WH, Lesser GJ, Laxton AW, Tatter SB, Debinski W, Chan MD. Comparison of clinical outcomes and genomic characteristics of single focus and multifocal glioblastoma. J Neurooncol. 2014 Sep; 119(2):429-35. PMID: 24990827.
      Citations:    
    35. Paulsson AK, McMullen KP, Peiffer AM, Hinson WH, Kearns WT, Johnson AJ, Lesser GJ, Ellis TL, Tatter SB, Debinski W, Shaw EG, Chan MD. Limited margins using modern radiotherapy techniques does not increase marginal failure rate of glioblastoma. Am J Clin Oncol. 2014 Apr; 37(2):177-81. PMID: 23211224.
      Citations:    
    36. Gmeiner WH, Lema-Tome C, Gibo D, Jennings-Gee J, Milligan C, Debinski W. Selective anti-tumor activity of the novel fluoropyrimidine polymer F10 towards G48a orthotopic GBM tumors. J Neurooncol. 2014 Feb; 116(3):447-54. PMID: 24346635.
      Citations:    
    37. Rossmeisl JH, Garcia PA, Daniel GB, Bourland JD, Debinski W, Dervisis N, Klahn S. Invited review--neuroimaging response assessment criteria for brain tumors in veterinary patients. Vet Radiol Ultrasound. 2014 Mar-Apr; 55(2):115-32. PMID: 24219161.
      Citations:    
    38. Debinski W, Dickinson P, Rossmeisl JH, Robertson J, Gibo DM. New agents for targeting of IL-13RA2 expressed in primary human and canine brain tumors. PLoS One. 2013; 8(10):e77719. PMID: 24147065.
      Citations:    
    39. Baiz D, Hassan S, Choi YA, Flores A, Karpova Y, Yancey D, Pullikuth A, Sui G, Sadelain M, Debinski W, Kulik G. Combination of the PI3K inhibitor ZSTK474 with a PSMA-targeted immunotoxin accelerates apoptosis and regression of prostate cancer. Neoplasia. 2013 Oct; 15(10):1172-83. PMID: 24204196.
      Citations:    
    40. Ferluga S, Hantgan R, Goldgur Y, Himanen JP, Nikolov DB, Debinski W. Biological and structural characterization of glycosylation on ephrin-A1, a preferred ligand for EphA2 receptor tyrosine kinase. J Biol Chem. 2013 Jun 21; 288(25):18448-57. PMID: 23661698.
      Citations:    
    41. Nguyen V, Conyers JM, Zhu D, Gibo DM, Hantgan RR, Larson SM, Debinski W, Mintz A. A novel ligand delivery system to non-invasively visualize and therapeutically exploit the IL13Ra2 tumor-restricted biomarker. Neuro Oncol. 2012 Oct; 14(10):1239-53. PMID: 22952195.
      Citations:    
    42. Pandya H, Debinski W. Toward intracellular targeted delivery of cancer therapeutics: progress and clinical outlook for brain tumor therapy. BioDrugs. 2012 Aug 01; 26(4):235-44. PMID: 22671766.
      Citations:    
    43. Beauchamp A, Lively MO, Mintz A, Gibo D, Wykosky J, Debinski W. EphrinA1 is released in three forms from cancer cells by matrix metalloproteases. Mol Cell Biol. 2012 Aug; 32(16):3253-64. PMID: 22688511.
      Citations:    
    44. Lema Tomé CM, Palma E, Ferluga S, Lowther WT, Hantgan R, Wykosky J, Debinski W. Structural and functional characterization of monomeric EphrinA1 binding site to EphA2 receptor. J Biol Chem. 2012 Apr 20; 287(17):14012-22. PMID: 22362770.
      Citations:    
    45. Nguyen V, Conyers JM, Zhu D, Gibo DM, Dorsey JF, Debinski W, Mintz A. IL-13Ra2-Targeted Therapy Escapees: Biologic and Therapeutic Implications. Transl Oncol. 2011 Dec; 4(6):390-400. PMID: 22191003.
      Citations:    
    46. Beauchamp A, Debinski W. Ephs and ephrins in cancer: ephrin-A1 signalling. Semin Cell Dev Biol. 2012 Feb; 23(1):109-15. PMID: 22040911.
      Citations:    
    47. Pandya H, Gibo DM, Garg S, Kridel S, Debinski W. An interleukin 13 receptor a 2-specific peptide homes to human Glioblastoma multiforme xenografts. Neuro Oncol. 2012 Jan; 14(1):6-18. PMID: 21946118.
      Citations:    
    48. Debinski W, Gibo DM. Fos-related antigen 1 (Fra-1) pairing with and transactivation of JunB in GBM cells. . 2011 Jan 15; 11(2):254-62. PMID: 21088499.
      Citations:    
    49. Debinski W, Tatter SB. Convection-enhanced delivery to achieve widespread distribution of viral vectors: Predicting clinical implementation. Curr Opin Mol Ther. 2010 Dec; 12(6):647-53. PMID: 21154156.
      Citations:    
    50. Candolfi M, Xiong W, Yagiz K, Liu C, Muhammad AK, Puntel M, Foulad D, Zadmehr A, Ahlzadeh GE, Kroeger KM, Tesarfreund M, Lee S, Debinski W, Sareen D, Svendsen CN, Rodriguez R, Lowenstein PR, Castro MG. Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics. Proc Natl Acad Sci U S A. 2010 Nov 16; 107(46):20021-6. PMID: 21030678.
      Citations:    
    51. Pandya H, Gibo DM, Debinski W. Molecular targeting of intracellular compartments specifically in cancer cells. Genes Cancer. 2010 May; 1(5):421-33. PMID: 20740056.
      Citations:    
    52. Debinski W, Tatter SB. Convection-enhanced delivery for the treatment of brain tumors. Expert Rev Neurother. 2009 Oct; 9(10):1519-27. PMID: 19831841.
      Citations:    
    53. Liu TF, Cai J, Gibo DM, Debinski W. Reoxygenation of hypoxic glioblastoma multiforme cells potentiates the killing effect of an interleukin-13-based cytotoxin. Clin Cancer Res. 2009 Jan 01; 15(1):160-8. PMID: 19118043.
      Citations:    
    54. Chen J, Zhuang G, Frieden L, Debinski W. Eph receptors and Ephrins in cancer: common themes and controversies. Cancer Res. 2008 Dec 15; 68(24):10031-3. PMID: 19074866.
      Citations:    
    55. Wykosky J, Debinski W. The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting. Mol Cancer Res. 2008 Dec; 6(12):1795-806. PMID: 19074825.
      Citations:    
    56. Mintz A, Gibo DM, Madhankumar AB, Cladel NM, Christensen ND, Debinski W. Protein- and DNA-based active immunotherapy targeting interleukin-13 receptor alpha2. Cancer Biother Radiopharm. 2008 Oct; 23(5):581-9. PMID: 18976118.
      Citations:    
    57. Debinski W. Drug cocktails for effective treatment of glioblastoma multiforme. Expert Rev Neurother. 2008 Apr; 8(4):515-7. PMID: 18416653.
      Citations:    
    58. Wykosky J, Gibo DM, Stanton C, Debinski W. Interleukin-13 receptor alpha 2, EphA2, and Fos-related antigen 1 as molecular denominators of high-grade astrocytomas and specific targets for combinatorial therapy. Clin Cancer Res. 2008 Jan 01; 14(1):199-208. PMID: 18172271.
      Citations:    
    59. Wykosky J, Gibo DM, Debinski W. A novel, potent, and specific ephrinA1-based cytotoxin against EphA2 receptor expressing tumor cells. . 2007 Dec; 6(12 Pt 1):3208-18. PMID: 18089715.
      Citations:    
    60. Schwartzbaum JA, Ahlbom A, Lönn S, Malmer B, Wigertz A, Auvinen A, Brookes AJ, Collatz Christensen H, Henriksson R, Johansen C, Salminen T, Schoemaker MJ, Swerdlow AJ, Debinski W, Feychting M. An international case-control study of interleukin-4Ralpha, interleukin-13, and cyclooxygenase-2 polymorphisms and glioblastoma risk. Cancer Epidemiol Biomarkers Prev. 2007 Nov; 16(11):2448-54. PMID: 18006935.
      Citations:    
    61. Debinski W. Naturally occurring, unmodified bacterial toxin for the treatment of glioblastoma multiforme? . 2006 Nov; 5(11):1569-70. PMID: 17204857.
      Citations:    
    62. Wykosky J, Gibo DM, Stanton C, Debinski W. EphA2 as a novel molecular marker and target in glioblastoma multiforme. Mol Cancer Res. 2005 Oct; 3(10):541-51. PMID: 16254188.
      Citations:    
    63. Debinski W. Personalized, multivalent, and more affordable: the globalization of vaccines. Clin Cancer Res. 2005 Aug 15; 11(16):5663-4. PMID: 16115899.
      Citations:    
    64. Schwartzbaum J, Ahlbom A, Malmer B, Lönn S, Brookes AJ, Doss H, Debinski W, Henriksson R, Feychting M. Polymorphisms associated with asthma are inversely related to glioblastoma multiforme. Cancer Res. 2005 Jul 15; 65(14):6459-65. PMID: 16024651.
      Citations:    
    65. Debinski W, Gibo DM. Fos-related antigen 1 modulates malignant features of glioma cells. Mol Cancer Res. 2005 Apr; 3(4):237-49. PMID: 15831677.
      Citations:    
    66. Madhankumar AB, Mintz A, Debinski W. Interleukin 13 mutants of enhanced avidity toward the glioma-associated receptor, IL13Ralpha2. Neoplasia. 2004 Jan-Feb; 6(1):15-22. PMID: 15068667.
      Citations:    
    67. Mintz A, Gibo DM, Madhankumar AB, Debinski W. Molecular targeting with recombinant cytotoxins of interleukin-13 receptor alpha2-expressing glioma. J Neurooncol. 2003 Aug-Sep; 64(1-2):117-23. PMID: 12952292.
      Citations:    
    68. Debinski W, Gibo D, Mintz A. Epigenetics in high-grade astrocytomas: opportunities for prevention and detection of brain tumors. Ann N Y Acad Sci. 2003 Mar; 983:232-42. PMID: 12724228.
      Citations:    
    69. Zhou G, Ye GJ, Debinski W, Roizman B. Engineered herpes simplex virus 1 is dependent on IL13Ralpha 2 receptor for cell entry and independent of glycoprotein D receptor interaction. Proc Natl Acad Sci U S A. 2002 Nov 12; 99(23):15124-9. PMID: 12417744.
      Citations:    
    70. Mintz A, Gibo DM, Slagle-Webb B, Christensen ND, Debinski W. IL-13Ralpha2 is a glioma-restricted receptor for interleukin-13. Neoplasia. 2002 Sep-Oct; 4(5):388-99. PMID: 12192597.
      Citations:    
    71. Madhankumar AB, Mintz A, Debinski W. Alanine-scanning mutagenesis of alpha-helix D segment of interleukin-13 reveals new functionally important residues of the cytokine. J Biol Chem. 2002 Nov 08; 277(45):43194-205. PMID: 12189139.
      Citations:    
    72. Debinski W. Local treatment of brain tumors with targeted chimera cytotoxic proteins. Cancer Invest. 2002; 20(5-6):801-9. PMID: 12197239.
      Citations:    
    Debinski's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (301)
    Explore
    _
    Co-Authors (34)
    Explore
    _
    Similar People (52)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _